Skip to main content
Log in

Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors

  • CASE REPORT
  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

During treatment with azithromycin, a 55 year-old woman developed a newly prolonged QT interval and torsade de pointes in the absence of known risk factors. Female gender and acute renal failure may be considerations in patients treated with azithromycin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Haverkamp, W., Breithardt, G. R., Camm, A. J., Janse, M. J., Rosen, M. R., Antzelevitch, C., et al. (2000). The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Cardiovascular Research, 47, 219–233.

    Article  PubMed  CAS  Google Scholar 

  2. Moss, A. J, Schwartz, P. J., Crampton, R. S., Tzivoni, D., Locati, E. H., MacCluer, J., et al. (1991). The long QT syndrome. Prospective longitudinal study of 328 families. Circulation, 84, 1136–1144.

    PubMed  CAS  Google Scholar 

  3. Brandriss, M. W., Richardson, W. S., & Barold, S. S. (1994). Erythromycin-induced QT prolongation and polymorphic tachycardia (torsades de pointes): Case report and review. Clinical Infectious Diseases, 18, 995–998.

    PubMed  CAS  Google Scholar 

  4. Lee, K. L., Jim, M. H., Tang, S. C., & Tai, Y. T. (1998). QT prolongation and Torsades de Pointes associated with clarithromycin. American Journal of Medicine, 104, 395–396.

    Article  PubMed  CAS  Google Scholar 

  5. Rubinstein, E. (2001). Comparative safety of the different macrolides. International Journal of Antimicrobial Agents, 18(Suppl 1), 71–76.

    Article  Google Scholar 

  6. Samarendra, P., Kumari, S., Evans, S. J., Sacchi, T. J., & Navaro, V. (2001). QT Prolongation Associated with Azithromycin/Amiodarone combination. PACE, 24, 1572–1574.

    PubMed  CAS  Google Scholar 

  7. Arellano-Rodrigo, E., Garcia, A., Mont, L., & Roque, M. (2001). Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome. Medical Clinic (Barc), 117, 118–119.

    CAS  Google Scholar 

  8. Matsunaga, N., Oki, Y., & Prigollini, A. (2003). A case of QT interval prolongation precipitated by azithromycin. New Zealand Medical Journal, 1, 1185–1186.

    Google Scholar 

  9. Strle, F., & Maraspin, V. (2002). Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr, 114, 396–399.

    PubMed  CAS  Google Scholar 

  10. Kim, M. H., Berkowitz, C., & Trohman, R. G. (2005). Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. PACE, 28, 1221–1222.

    PubMed  Google Scholar 

  11. Milberg, P., Eckardt, L., Bruns, H. J., Biertz, J., Ramtin, S., Reinsch, N., et al. (2002). Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. Journal of Pharmacology and Experimental Therapeutics, 303, 218–225.

    Article  PubMed  CAS  Google Scholar 

  12. Eckardt, L., Breithardt, G., & Haverkamp, W. (2002). Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: Low torsadogenic potential despite QT-prolongation. Journal of Pharmacology and Experimental Therapeutics, 300, 64–71.

    Article  PubMed  CAS  Google Scholar 

  13. Höffler, D., Paeske, B., & Koeppe, P. (1995). Pharmacokinetics of azithromycin in normal and impaired renal function. Infection, 23, 356–361.

    Article  PubMed  Google Scholar 

  14. Bonnar, C. E., Davie, A. P., Caruana, L., Fenn, L., Ogston, S. A., McMurray, J. J. V., et al. (1999). QT dispersion in patients with chronic heart failure: β Blockers are associated with a reduction in QT dispersion. Heart, 81, 297–302.

    PubMed  CAS  Google Scholar 

  15. Ex Card Research http://www.qtdrugs.com

  16. Drici, M. D., Knollmann, B. C., Wang, W. X., & Woosley, R. L. (1998). Cardiac actions of erythromycin: Influence of female sex. Journal of the American Medical Association, 280, 1774–1776.

    Article  PubMed  CAS  Google Scholar 

  17. Makkar, R. R., Fromm, B. S., Steinman, R. T., Meissner, M. D., & Lehmann, M. H. (1993). Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Journal of the American Medical Association, 270, 2590–2597.

    Article  PubMed  CAS  Google Scholar 

  18. Lorincz, I., Matyus, J., Zilahi, Z., Kun, C., Karanyi, Z., & Kakuk, G. (1999). QT dispersion in patients with end-stage renal failure and during hemodialysis. Journal of the American Medical Association, 10, 1297–1302.

    CAS  Google Scholar 

  19. Ozdemir, D., Mese, T., Agin, H., Calkavur, S., & Bak, M. (2005). Impact of haemodialysis on ATc dispersion in children. Nephrology, 10, 119–122.

    Article  PubMed  Google Scholar 

  20. Sarlagadda, S., & Perazella, M. (2006). Acute renal failure in the hospital: Diagnosis and management. Hospital Physician, 51–58.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John D. Fisher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kezerashvili, A., Khattak, H., Barsky, A. et al. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 18, 243–246 (2007). https://doi.org/10.1007/s10840-007-9124-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-007-9124-y

Keywords

Navigation